Danaher Co. (NYSE:DHR) Shares Acquired by Daymark Wealth Partners LLC

Daymark Wealth Partners LLC boosted its holdings in Danaher Co. (NYSE:DHR) by 5.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,366 shares of the conglomerate’s stock after buying an additional 868 shares during the quarter. Daymark Wealth Partners LLC’s holdings in Danaher were worth $4,828,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Lighthouse Investment Partners LLC purchased a new stake in Danaher in the 4th quarter worth approximately $624,000. Icon Wealth Advisors LLC acquired a new stake in Danaher in the fourth quarter valued at approximately $594,000. Ethic Inc. grew its position in Danaher by 1.1% in the fourth quarter. Ethic Inc. now owns 36,300 shares of the conglomerate’s stock worth $8,398,000 after acquiring an additional 389 shares in the last quarter. L1 Capital International Pty Ltd acquired a new position in shares of Danaher during the 4th quarter worth $7,627,000. Finally, First Financial Bankshares Inc bought a new position in shares of Danaher during the 4th quarter valued at $9,419,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

NYSE DHR traded up $0.65 on Wednesday, hitting $269.46. 317,891 shares of the company were exchanged, compared to its average volume of 2,732,096. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company has a market cap of $199.59 billion, a P/E ratio of 45.56, a P/E/G ratio of 4.55 and a beta of 0.83. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The firm has a 50 day moving average of $270.89 and a two-hundred day moving average of $258.85.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the business posted $2.05 earnings per share. Danaher’s revenue for the quarter was down 2.9% compared to the same quarter last year. On average, equities analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Activity at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 over the last 90 days. Insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on DHR. Wells Fargo & Company assumed coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price on the stock. Evercore ISI lifted their price target on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Stifel Nicolaus upped their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Barclays upped their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.